scholarly journals Utilization of epidermal growth factor receptor (EGFR) testing in the United States: a case study of T3 translational research

2013 ◽  
Vol 15 (8) ◽  
pp. 630-638 ◽  
Author(s):  
Julie A. Lynch ◽  
Muin J. Khoury ◽  
Ann Borzecki ◽  
Jerry Cromwell ◽  
Laura L. Hayman ◽  
...  
Keyword(s):  
United States ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Translational Research ◽  
Growth Factor Receptor ◽  
The United States ◽  
Epidermal Growth

Breast cancer drug trastuzumab induces cardiac toxicity: evaluation of human epidermal growth factor receptor 2 as a potential diagnostic and prognostic marker

2018 ◽  
Vol 96 (7) ◽  
pp. 647-654 ◽  
Author(s):  
Taylor A. Johnson ◽  
Dinender K. Singla
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Side Effects ◽  
Epidermal Growth Factor ◽  
Cardiac Toxicity ◽  
Growth Factor Receptor ◽  
The United States ◽  
Human Epidermal Growth Factor ◽  
Epidermal Growth

Breast cancer is one of the most prevalent forms of cancer in the United States and worldwide. Cancer occurs through the uncontrolled development of new abnormal cell growth. Clinicians and researchers strive to improve diagnostics and treatments in pursuit of remedying breast cancer, while limiting or removing any potential side effects that may arise. Unfortunately, traditional treatments, such as anthracyclines (i.e., doxorubicin), can damage the cardiovascular system. Recent strategies have utilized antibody-based compounds as singular treatments, or in conjunction with other treatments, with the aim to minimize side effects. The human epidermal growth factor receptor 2 (HER2) protein has been the target of numerous antibody-based breast cancer therapies, such as trastuzumab (TZM) and trastuzumab emtansine (T-DM1). This review will discuss the HER2 receptor as a diagnostic marker in targeting breast cancer using the therapeutic agents TZM and T-DM1, as well as discuss the induced cardiac toxicity following TZM and T-DM1 treatments.

scholarly journals Novel Drugs Targeting the Epidermal Growth Factor Receptor and Its Downstream Pathways in the Treatment of Colorectal Cancer: A Systematic Review

2012 ◽  
Vol 2012 ◽  
pp. 1-11 ◽  
Author(s):  
Amartej Merla ◽  
Sanjay Goel
Keyword(s):  
Colorectal Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Metastatic Colorectal Cancer ◽  
Growth Factor Receptor ◽  
The United States ◽  
Targeted Agents ◽  
The Future ◽  
Epidermal Growth

Colorectal cancer is the second most common malignancy among men and women in the United States, and the 5-year survival rate remains poor despite recent advances in chemotherapy and targeted agents. The mainstay of therapy for advanced disease remains the cytotoxic chemotherapy including 5-FU, irinotecan, and oxaliplatin. The USFDA approval and introduction of targeted therapies, including cetuximab and panitumumab (monoclonal antibodies targeting the epidermal growth factor receptor (EGFR)) and bevacizumab (monoclonal antibody targeting the vascular epithelial growth factor (VEGF)), has improved the median survival of patients with metastatic colorectal cancer to around 24 months. Clearly, better and more efficacious drugs are needed, and target-specific agents remain the future of cancer treatment. On this front, rapid advances are being made, which are likely to change the future of the management of metastatic colorectal cancer. However, absence of specific biomarkers for the use of targeted agents, in the subset of population who will benefit from the treatment, remains a major drawback. In this paper, we review agents that are in phases 1 and 2 clinical development, specifically targeting the EGFR and its subsequent downstream pathways.

Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study

2015 ◽  
Vol 58 (22) ◽  
pp. 8877-8895 ◽  
Author(s):  
Robert Heald ◽  
Krista K. Bowman ◽  
Marian C. Bryan ◽  
Daniel Burdick ◽  
Bryan Chan ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Lead Optimization ◽  
Epidermal Growth

scholarly journals Correction to Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study

2016 ◽  
Vol 59 (6) ◽  
pp. 2848-2848
Author(s):  
Robert Heald ◽  
Krista K. Bowman ◽  
Marian C. Bryan ◽  
Daniel Burdick ◽  
Bryan Chan ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Lead Optimization ◽  
Epidermal Growth
Sign in / Sign up

Export Citation Format

Share Document